The authors from The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, investigated the association between cuproptosis, a copper-induced mechanism of mitochondrial-related cell death, and long non-coding RNA (lncRNA) in lung squamous cell carcinoma (LUSC). Cuproptosis has shown potential in cancer treatment, and lncRNAs have been found to play a role in changing the biological activities of tumor cells. Until now, it was not known whether lncRNAs were associated with cuproptosis in LUSC.
LUSC is one of the most difficult tumors to treat, and the authors aimed to develop a signature based on cuproptosis-associated lncRNAs that could predict the prognosis of LUSC and investigate the immunological characteristics of LUSC. The study analyzed 49 normal samples and 502 tumor samples obtained from online databases. The researchers found that a signature consisting of three cuproptosis-related lncRNAs: AC002467.1, LINC01740, and LINC02345, could accurately predict the prognosis of patients with LUSC. Additionally, they used the signature to assess the prognostic risk of patients with LUSC and found that individuals with low-risk scores may benefit from immunotherapy.
The study also found that patients with LUSC who had more mutated risk genes in their bodies had a worse prognosis. These findings suggest that the predictive model based on the three identified lncRNAs is a satisfactory indicator for assessing the prognosis and immunotherapy of LUSC.
The study’s lead authors expressed hope that these findings would lead to further research in drug development against LUSC based on the identified lncRNAs. “I believe it will be very exciting to see the results when they become available,” Qing Lou stated.
The study’s findings have important implications for cancer research and treatment and offer hope for improving outcomes for patients with LUSC.
Reference: Hou C, Wu X, Li C, Wang C, Liu J, Luo Q. A cuproptosis-associated long non-coding RNA signature for the prognosis and immunotherapy of lung squamous cell carcinoma. Biomol Biomed [Internet]. 2023Jan.15 [cited 2023Apr.26];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/8481
Editor: Ermina Vukalic